Leuk Res. Hu X, Yang Y, Chen L, Wan Y, Sheng L, Bao Y, Zheng M. Am J Transl Res. NCI CPTC Antibody Characterization Program. Usually, 1 to 1.5 mL of spinal fluid is sufficient. Cytometry B Clin Cytom. doi: 10.1371/journal.pone.0158827. Available online through https://www.lls.org. The site is secure. PMC J Adv Pract Oncol. Acute Leukemia. -, N Engl J Med. National Library of Medicine Submission of bilateral specimens is not required. http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=341450, http://www.nature.com/leu/journal/v20/n7/full/2404242a.html, http://www.bloodjournal.org/content/96/3/870?sso-checked=true. Before They do not die at a normal rate, so they accumulate in the bone marrow, lymph nodes, or other tissues. Specimen Stability Information: Ambient/Refrigerated < or =96 hours, Slides: If possible, include 5 to 10 unstained bone marrow aspirate smears labeled with two unique identifiers. A stable aberrant immunophenotype characterizes nearly all cases of Leukemia & Lymphoma Society [On-line information]. Treatment of plasma cell neoplasms (including multiple myeloma, monoclonal gammopathy of undetermined significance, and plasmacytoma) includes observation, chemotherapy, radiation therapy, stem cell rescue, targeted therapy, immunotherapy, and supportive therapies. Disclaimer. ( 2011). Immunophenotypically, both NHLs lacked surface Ig heavy chains. The https:// ensures that you are connecting to the Diverse Immunophenotypic Abnormalities in Adult Patients with No significant immunophenotypic abnormality was detected by flow cytometry. As the number of abnormal cells increase in a lymph node, the size of the lymph node increases. (+632) 7110427 | (+632) 7110383 This can happen spontaneously. This technique also helps identify or confirm the cell of origin in non-hematopoietic neoplasia. Cancers (Basel). Specific features were seen in five ANLL entities: M0 or M1/B lineage antigen positivity/t(9;22) or del(11)(q23); M2/CD13-/t(8;21); M4/CD13+, CD34+, CD36+/inv(16); M4 or M5/lack of B lineage antigen/del(11)(q23) or t(9;11). It depends. 2. Shi M, Jevremovic D, Otteson GE, Timm MM, Olteanu H, Horna P: Single antibody detection of T-cell receptor alpha beta clonality by flow cytometry rapidly identifies mature T-cell neoplasms and monotypic small CD8-positive subsets of uncertain significance. Immunophenotyping is widely used for the following reasons: To differentiate between: Acute myeloid and lymphoid leukemia B and T cell lymphoid neoplasms such as chronic lymphocytic leukemia and. For bone marrow testing, if cytogenetic tests are desired along with this test request, an additional specimen should be submitted. Copyright 2013 Integrity Aesthetic & Wellness Center. The results may also be used to predict how aggressive the cancer will be and/or whether it will respond to certain treatment. If additional testing is required, it will be added per the algorithm to fully characterize a disease state with a charge per unique antibody tested. A laboratory report will typically include specific results from the tests as well as an analysis of what those results mean. Owned and operated by AZoNetwork, 2000-2023. Clipboard, Search History, and several other advanced features are temporarily unavailable. MeSH terms Chromosome Aberrations The course of treatment for your cancer will be determined by your health care practitioner and their team based on flow cytometry immunophenotyping and other tests that might be performed. MedlinePlus Medical Encyclopedia [On-line information]. Two or more immunophenotypic abnormalities were detected in 49 of 81 RCC patients (60%), and in 2 of 17 (v)SAA patients (12%). In our case report, a middle-aged male . Flow cytometry may be used to characterize and count types of white blood cells in the evaluation of infectious diseases, autoimmune disorders or immunodeficiencies. Cheriyedath, Susha. Siba El Hussein, Keyur P. Patel, Hong Fang, Beenu Thakral, Sanam Loghavi, Rashmi Kanagal-Shamanna, Sergej Konoplev, Elias J. Jabbour, L. J. Jeffrey Medeiros, Joseph D. Khoury Furthermore, these findings can also be seen Incidence of peripheral lymphadenopathy, hepatic abnormalities, splenic abnormalities, and abdominal lymphadenopathy was not significantly different among immunophenotypic groups. Maecker, H. et. HHS Vulnerability Disclosure, Help In: McClatchey KD, ed. 3. Available online at https://www.cancer.org/cancer/leukemia-in-children/detection-diagnosis-staging/how-diagnosed.html. The triage panel is initially performed to evaluate for monotypic B cells by kappa and lambda light chain expression, increased numbers of blast cells by CD34 and CD45 expression along with side scatter gating, and increased plasma cells by CD45 expression and side scatter gating. The blood of an older child or adult normally contains some mature B cells, but circulating immature B cells are not normally present. Flow leukemia can be used in the case of an extensive range of leukemias that could be myeloid or lymphoid. Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia. Flow cytometry is generally used as follow up testing after a complete blood count (CBC) or white blood cells scan . Overall, del(13q14) and +12 were the most common abnormalities (39%), whereas del(11q13), del(17p13), and del(6q23) were detected only in 3, 1, and 0 cases, respectively. This case suggested that chromosomal alterations may precede morphological, flow cytometric and clinical changes and accelerate progression of the disease. Please enable it to take advantage of the complete set of features! Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes 7 In summary, blasts of AMoL can be. . Immunophenotypic analysis of non-Hodgkin's lymphomas. An interpretation of the immunophenotypic findings and correlation with the morphologic features will be provided by a hematopathologist for every case. Pertinent clinical history including reason for testing or clinical indication. Pp 244-247. The .gov means its official. Immunophenotypic diagnosis of non-Hodgkin's lymphoma in paraffin sections. Available online at https://www.mayoclinic.com/health/chronic-lymphocytic-leukemia/DS00565. There is increasing evidence of T cell dysfunction in B cell chronic lymphocytic leukaemia (B-CLL) which may contribute to the aetiology and progress of the disease. Available online at https://emedicine.medscape.com/article/207631-overview. [On-line information]. Send whole blood specimen in original tube. It has become a common technique for the identification and classification of acute leukemias, particularly acute myeloid leukemia (AML). MeSH 1. Immunologic monitoring in adults with acute lymphoblastic leukemia. 2. -T-cell receptor gene rearrangement to examine clonality of T cells in cases showing phenotypically aberrant T-cell population. There is a dim Kappa expression and dim CD20 expression. Now, if an adult has a small number of mature B cells but also has a large number of immature B cells which are positive for CD19 (remember, CD19 is a B-cell marker) and also positive for both CD34 and CD20 (which identifies those cells are both immature and abnormal), then the personhasan immature B-cell leukemia known as B-lymphoblastic leukemia. I just had a colposcopy done to follow up on an ASCUS pap with high risk HPV. An absolute CD8+ lymphocytosis correlates with disease progression and low expression of CD4 and CD8 (as found in autoimmune disease) The study was aimed to investigate the immunophenotypic and cytogenetic features of chronic lymphocytic leukemia (CLL) in order to provide an evidence for diagnosis and therapy. Accessed April 2011. Available online at https://www.cancer.org/acs/groups/cid/documents/webcontent/003109-pdf.pdf. 1. In this case report of a child with mosaic T21 and DS-AMKL, flow cytometry performed on BMA showed no immunophenotypic abnormalities, morphological review of BMA revealed no clusters of tumor cells, and BMA failed to show the expected GATA1 mutation. Please enable it to take advantage of the complete set of features! Testing may be done when you have signs and symptoms of leukemia and lymphoma, though they may be unremarkable, mild, or nonspecific early in the disease. Standardizing immunophenotyping for the Human Immunology Project. MDS is distinguished from other disease processes by a pattern of multiple myeloid immunophenotypic abnormalities (3-6). [Importance of cytogenetics in the study of acute non-lymphoblastic leukemias]. Accessed December 2014. This technique helps identify the lineage of cells using antibodies that detect markers or antigens on the cells, hence the immuno- prefix. Unauthorized use of these marks is strictly prohibited. Blood. An abnormal karyotype was detected in 232 cases (54%). Chronic lymphocytic leukemia is an extremely heterogeneous disease and prognostic factors such as chromosomal abnormalities are important predictors of time to first treatment and survival. Accessed December 2014. 8600 Rockville Pike 2013 Jan;92(1):89-96. doi: 10.1007/s00277-012-1574-3. Epub 2018 May 7. Lamb, A. et. Bahler, D. (Updated 2011 February). Stay up to date with the latest news and information from Testing.com by subscribing to our newsletter. low reading R03.1 . (Blood cells normally mature in the bone marrow and are released into circulation when they are mature or nearly mature.) A cell count should be determined and submitted with the specimen. Accessed January 2020. Immunophenotypic patterns and cytogenetic anomalies in acute non 2018 Jun 1;128(6):2519-2534. doi: 10.1172/JCI97053. 2010 May;34(5):594-7. doi: 10.1016/j.leukres.2009.08.029. Careers. Co-expression of L60 (Leu-22) and L26 antigens correlates with malignant histologic findings. National Library of Medicine If no abnormalities are detected by the initial panel, no further flow cytometric assessment will be performed unless otherwise indicated by specific features of the clinical presentation or prior laboratory results. 2010 Sep;34(9):1235-1238. doi: 10.1016/j.leukres.2010.03.020, 2. News-Medical, viewed 04 March 2023, https://www.news-medical.net/health/What-is-Immunophenotyping.aspx. An abnormal karyotype was detected in 232 cases (54%). Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Flow cytometric analysis of the peripheral blood shows no immunophenotypic evidence for an abnormal B cell or T- cell population, and no circulating blasts. It is also suggested to have prognostic significance [ 2]. Imamura N, Kusunoki Y, Oda K, Abe K, Dohi H, Inada T, Kuramoto A, Kajihara H, Fujii H, Kawa K, et al. Accessed April 2011. If no abnormalities are detected by the initial panel, no further flow cytometric assessment will be performed unless otherwise indicated by specific features of the clinical presentation or prior laboratory results. A pathologist, often one specializing in the study of blood diseases and/or blood cell cancers (a hematopathologist), will consider the results from the complete blood count (CBC), differential, blood smear, bone marrow findings, and flow cytometry immunophenotyping as well as other tests in order to provide a diagnostic interpretation. Accessed January 2020. Evaluating lymphocytoses of undetermined etiology, Identifying B- and T-cell lymphoproliferative disorders involving blood and bone marrow Distinguishing acute lymphoblastic leukemia (ALL) from acute myeloid leukemia (AML) Immunologic subtyping of ALL Distinguishing reactive lymphocytes and lymphoid hyperplasia from malignant lymphoma Distinguishing between malignant lymphoma and acute leukemia Phenotypic subclassification of B- and T-cell chronic lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia Recognizing AML with minimal morphologic or cytochemical evidence of differentiation Recognizing monoclonal plasma cells, Identifying B- and T-cell lymphoproliferative disorders involving blood and bone marrow, Distinguishing acute lymphoblastic leukemia (ALL) from acute myeloid leukemia (AML) Immunologic subtyping of ALL Distinguishing reactive lymphocytes and lymphoid hyperplasia from malignant lymphoma Distinguishing between malignant lymphoma and acute leukemia Phenotypic subclassification of B- and T-cell chronic lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia Recognizing AML with minimal morphologic or cytochemical evidence of differentiation Recognizing monoclonal plasma cells, Distinguishing acute lymphoblastic leukemia (ALL) from acute myeloid leukemia (AML), Immunologic subtyping of ALL Distinguishing reactive lymphocytes and lymphoid hyperplasia from malignant lymphoma Distinguishing between malignant lymphoma and acute leukemia Phenotypic subclassification of B- and T-cell chronic lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia Recognizing AML with minimal morphologic or cytochemical evidence of differentiation Recognizing monoclonal plasma cells, Distinguishing reactive lymphocytes and lymphoid hyperplasia from malignant lymphoma Distinguishing between malignant lymphoma and acute leukemia Phenotypic subclassification of B- and T-cell chronic lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia Recognizing AML with minimal morphologic or cytochemical evidence of differentiation Recognizing monoclonal plasma cells, Distinguishing reactive lymphocytes and lymphoid hyperplasia from malignant lymphoma, Distinguishing between malignant lymphoma and acute leukemia Phenotypic subclassification of B- and T-cell chronic lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia Recognizing AML with minimal morphologic or cytochemical evidence of differentiation Recognizing monoclonal plasma cells, Distinguishing between malignant lymphoma and acute leukemia, Phenotypic subclassification of B- and T-cell chronic lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia Recognizing AML with minimal morphologic or cytochemical evidence of differentiation Recognizing monoclonal plasma cells, Phenotypic subclassification of B- and T-cell chronic lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia, Recognizing AML with minimal morphologic or cytochemical evidence of differentiation Recognizing monoclonal plasma cells, Recognizing AML with minimal morphologic or cytochemical evidence of differentiation. Each persons condition will be unique. 9. Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases. The results of this study were compared with other clinical and biological features. This study examines the immunohistologic profiles of a large series of histologically proven benign and malignant lymphoproliferative processes in order to define immunophenotypic criteria useful in the diagnosis of non-Hodgkin's lymphoma. government site. By junio 4, 2022 masonry pilaster details junio 4, 2022 masonry pilaster details Accessed April 2011. Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis. . This process is widely used to diagnose different types of lymphoma and leukemia by comparing normal cells and cancer cells. Jiang NG, Jin YM, Niu Q, Zeng TT, Su J, Zhu HL. The immunophenotype of ANKL cells may differ from reactive NK cells in 4 respects. 2016 Aug 2;11(8):e0158827. 2022 Feb 15;12(1):17-32. eCollection 2022. ( 2006). Available online at https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. The third parameter for assessing dysplasia by flow cytometry is maturation pattern of granulocytes on CD13/CD16 plot. Monoclonal B-cell lymphocytosis (MBL) is defined as a laboratory abnormality where small (<5 x 10(9)/L) clonal B-cell populations are detected in the peripheral blood of otherwise healthy subjects. Body fluid samples are obtained through collection of the fluid in a container or by inserting a needle into the body cavity and aspirating a portion of the fluid with a syringe. Please use one of the following formats to cite this article in your essay, paper or report: Cheriyedath, Susha. Front Oncol. 1. Craig, F. and Foon, K. (2008 April 15). These plasma cells are negative for CD19. and transmitted securely. Epub 2012 Sep 20. In general, these criteria involved identification of abnormal expression or loss of antigens in B- and T-lineage populations. no immunophenotypic abnormalities detected FREE COVID TEST lansing school district spring break 2021 Book Appointment Now. 2021 Jun 7;22(7):60. doi: 10.1007/s11864-021-00857-w. J Oral Maxillofac Pathol. Available online at https://www.clinchem.org/cgi/content/full/46/8/1221. Application of these criteria to a series of nearly 500 cases of lymphoma indicated that over 90% of B-lineage and about 80% of T-lineage neoplasms manifested immunophenotypic abnormalities that could distinguish them from benign, reactive lymphoid processes. CD38 expression is not detected (<10%) No evidence of p53 (17p13) 4. Clinical review on features and cytogenetic patterns in adult acute myeloid leukemia with lymphoid markers. official website and that any information you provide is encrypted Label specimen as spinal . It may be because the markers of interest are not available for flow cytometryor because fresh cells or tissue are not available (a requirement for flow cytometry immunophenotyping). -TCL-1 break-apart at 14q32, to exclude T-cell prolymphocytic leukemia in cases with CD4-positive T-cell lymphoproliferative disorder (phenotypic aberrancy or very tight CD4+ population with high CD4:CD8 ratio). Flow cytometric immunophenotyping performed on this bone marrow specimen demonstrated a small polytypic plasma cell population with no immunophenotypic abnormalities except the anticipated CD38 negativity due to the effect of daratumumab. Szary syndrome with multiple immunophenotypic aberrancies in tumor cells. 88184-Flow cytometry; first cell surface, cytoplasmic or nuclear marker x 1, 88185-Flow cytometry; additional cell surface, cytoplasmic or nuclear marker (each), 88187-Flow Cytometry Interpretation, 2 to 8 Markers (if appropriate), 88188-Flow Cytometry Interpretation, 9 to 15 Markers (if appropriate), 88189-Flow Cytometry Interpretation, 16 or More Markers (if appropriate), Normal Reports | Immunophenotyping hematopoietic specimens can help resolve many differential diagnostic problems posed by the clinical or morphologic features. The results of flow cytometry or immunocytochemistry should always be interpreted along with the available medical history, clinical signs, imaging findings, and pathologic results of individual cases. Classification of MDS patients according to the patterns of expression of multiple. All rights reserved. Would you like email updates of new search results? no immunophenotypic abnormalities detected, failed to save changes to sbc squad companion app. An official website of the United States government. National Cancer Institute [On-line information]. If the CT scan said that there are no significant abnormalities it means that nothing out of the ordinary was noted. It can detect normal cells as well as abnormal cells whose pattern of markers are typically seen with specific types of leukemia and lymphoma. Diagnosis of malignant lymphoma - An overview. Accessibility Flow cytometric immunophenotyping is an established method for the detection of occult leptomeningeal disease in patients with aggressive B-cell non-Hodgkin lymphoma, and is increasingly being used in the evaluation of patients without an established diagnosis of lymphoma who present with signs and/or symptoms referable to the central nervous 1998 Feb;109(2):211-20. doi: 10.1093/ajcp/109.2.211. 4th ed. PDF available for download at https://jama.ama-assn.org/content/301/4/452.full.pdf. Disclaimer. Leukemia & Lymphoma Society [On-line information]. June 10, 2022 heart medicine dandelions and roundup. Bethesda, MD 20894, Web Policies Unauthorized use of these marks is strictly prohibited. 2019 Aug 6;9:713. doi: 10.3389/fonc.2019.00713. These abnormal populations, detected only by flow cytometry, comprised 1 and 2% of total white blood cells and were discrete CD4-dim CD26-negative T-cell populations. Blood Tests. eCollection 2022. Please enable it to take advantage of the complete set of features! This is the most common type of abnormal Pap smear. Cancer Immunol Immunother. More info. 1985 Apr;65(4):974-83 al. Morphologic evaluation and flow cytometric immunophenotypic analysis revealed no evidence of plasma cell neoplasm involving the BM. Additional FISH or molecular testing may be recommended by the Mayo pathologist to facilitate diagnosis. No abnormalities were detected for the other phenotypic markers analyzed, including 7.1 ( Table 2 ). Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954680/. Last, the positive rate of Ki-67 expression in ANKL cells was generally high. It's also used to diagnose and classify leukemia or lymphoma. Large granular lymphocytic leukemia: a brief review. no immunophenotypic abnormalities detected Am J Med. More practically, and although the relationships demonstrated only represent a fraction of homogeneous immunophenotypic subgroups, identification of such immunophenotypic features should prompt careful karyotypic examination, eventually using molecular biology analysis on non-growing cells. This test is appropriate for hematopoietic specimens only. 2018 Oct;17(10):2226-2237. doi: 10.1158/1535-7163.MCT-18-0426. Immunophenotyping is a test used to identify cells on the basis of the types of markers or antigens present on the cells surface, nucleus, or cytoplasm. 1990 Oct;81(10):629-34. In agreement with previous studies, no immunophenotypic features (other than monocytic differentiation) predicted the presence of an 11q23 rearrangement. The results from your immunophenotyping are compared to the pattern of antigens for normal cells as well as to patterns that are associated with abnormal cells (e.g., cells present with leukemias and lymphomas). This category is to be used to record an episode of elevated blood pressure in a patient in whom no formal diagnosis of hypertension has been made, or as an isolated incidental finding. Flow Cytometry: Test, Use, Analysis & Results Interpretation What is Immunophenotyping?. Compilation of the top interviews, articles, and news in the last year. First, the CD45/linear side scatter gating of flow cytometry allows the initial identification of neoplastic subpopulations for additional immunophenotypic analysis in half of ANKL cases. Lymphoma Phenotyping. (Reviewed 2013 July 10). Upper endoscopy revealed a neoplastic growth at . Trisomy 12 is the second most frequent aberration detected by fluorescence in situ hybridization at the time of diagnosis (10-25%), and it confers an intermediate prognostic risk, with a median time to . Immunophenotyping is widely used for the following reasons: Two types of tests are used in immunophenotyping: The choice of test is based on the type of sample: Heres a brief overview of the two types of test methods: In flow cytometry, the sample may range from blood, fluids in the body cavity (such as peritoneal or pleural fluids), bone marrow, or solid tissues in liquid media. If possible, fluids other than spinal fluid should be anticoagulated with heparin (1 U/mL of fluid). ( 2015). Bookshelf The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. no immunophenotypic abnormalities detected - tecnogin.com Accessed April 2011. These may be the first indication of a possible blood cell cancer. al. Available online at https://www.arupconsult.com/Topics/LymphomaPhenotyping.html. (2018 October 17, Revised). Acute Lymphoblastic Leukemia. (accessed March 04, 2023). [On-line information]. Leukemia/Lymphoma Immunophenotyping, Flow Cytometry, Varies - St Two atypical human non-Hodgkin's lymphomas (NHLs) that exhibited unusual genotypic and in situ immunophenotypic abnormalities are described. 2008 December 1; 112(12): 43844399. This test will be processed as a laboratory consultation. official website and that any information you provide is encrypted 2009 Dec;29(6):491-6. doi: 10.3343/kjlm.2009.29.6.491. ( 19952011). government site. ( 19952014). A bone marrow sample may be collected from the hip bone by a trained health care practitioner (Bone Marrow Aspiration and Biopsy). bumgarner funeral home obituaries no immunophenotypic abnormalities detected. Furthermore, these findings can also be seen I got thre results today, which were "no significant abnormalities". Flow cytometry immunophenotyping is used primarily to help diagnose and classify blood cell cancers (leukemias and lymphomas) and to help guide their treatment. Rinsho Ketsueki. In this interview, AZoM speaks to Rohan Thakur, the President of Life Science Mass Spectrometry at Bruker, about what the opportunities of the market are and how Bruker is planning on rising to the challenge. What is Immunophenotyping? - News-Medical.net The screening panel will be charged based on the number of markers tested (FIRST for first marker, ADD1 for each additional marker). (2019 January 3, Updated). The t(14;19)(q32;q13) involving the IGH@ and BCL3 loci is an infrequent cytogenetic abnormality detected in B-cell malignancies. (2009 January 28). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. This approach generally uses less antibodies than the shotgun approach but can be more time consuming. Ngan BY, Picker LJ, Medeiros LJ, Warnke RA. Curr Treat Options Oncol. American Society for Clinical Pathology; 2007; Betters DM: Use of flow cytometry in clinical practice. Flow cytometric immunophenotyping is a valuable addition to morphology in the diagnosis of MDS in adults.7 Abnormalities detected by flow cytometry in myelomonocytic, . (FNA09-1171; 9/30/09): No monotypic B cell population, phenotypically abnormal T cell population, or blast cell population detected. Specimen must arrive within 96 hours of collection. (2012 February 17). -Bone Marrow Staging for Known or Suspected Malignant Lymphoma Algorithm, -Acute Myeloid Leukemia: Testing Algorithm, -Acute Myeloid Leukemia: Relapsed with Previous Remission Testing Algorithm, -Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up, -Mast Cell Disorder: Diagnostic Algorithm, Bone Marrow, -Acute Leukemias of Ambiguous Lineage Testing Algorithm, Acute Leukemia -- Immunophenotyping, Flow Cytometry, Chronic Lymphocytic Leukemia, Immunophenotyping, Flow Cytometry, Flow Cytometry, Leukemia Immunophenotyping, Flow Cytometry, Lymphoma Immunophenotyping, Lymphoma Immunophenotyping by Flow Cytometry, GLL Panel - Leukemia Immunophenotyping (ALWAYS order LCMS), Granular Lymphocytic Leukemia (ALWAYS order LCMS), KIR Panel - Leukemia Immunophenotyping (ALWAYS order LCMS), LGL Panel - Leukemia Immunophenotyping (ALWAYS order LCMS), NK Panel - Leukemia Immunophenotyping (ALWAYS order LCMS), B-cell ALL minimal residual disease (MRD) detection. [Aggressive natural killer cell leukemia/lymphoma--possible existence of a new clinical entity originating from the third lineage of lymphoid cells].